The prestigious American College of Cardiology (ACC) did not accept a controversial study of Merck and Schering-Plough's Vytorin as a highlighted presentation at its annual meeting in March, a key showcase for data on heart drugs, but the group plans to include the presentation at its meeting in some other form.
Schering-Plough faces a U.S. delay on its anesthesia drug sugammadex and declining sales of the cholesterol drugs Zetia and Vytorin, which it sells with Merck.